Published : 16 Mar 2026
Aagami has received a new assignment from their publicly listed Japanese client, to establish R&D collaborations/Licensing partnerships for their proprietary Novel Drug Delivery system - Ionic Liquid (IL) technology platform enabling transdermal and oral delivery of complex modalities.
The client’s Novel Drug Delivery System - Ionic Liquid (IL) delivery technology solves major solubility and permeability hurdles without causing tissue irritation.
Highlights:
· World-First Innovation: First company globally to apply ionic liquids to pharmaceutical preparations and clinical trials.
· Dual Delivery Routes: Specialized IL systems for both Transdermal (ILTS) and Oral drug delivery.
· Transdermal Delivery: Delivered a 12kDa Decoy ODN topically with proven Phase 1 safety, as well as osteoporosis drug Teriparatide.
· Superior Skin Permeability: Facilitates penetration of large molecules (e.g., Teriparatide, 4.0kDa) without topical irritation.
· Overcoming Solubility Hurdles: Solves API challenges regarding solubility, absorption, and metabolic effects.
· Broad Modality Compatibility: Applicable to low-molecular compounds, protein peptides, vaccines, and RNA therapeutics.
· Enhanced Oral Bioavailability: Demonstrated 6-fold improvement in bioavailability for middle-molecule drugs like Semaglutide. [Semaglutide vs. Rybelsus in vivo].
· Flexible Collaboration Model: R&D collaboration and licensing available for worldwide research partnerships
Client has been very happy with Aagami’s support and has awarded multiple assignments so far, this one being the latest.
We are confident that the Bio Pharma industry would benefit from their impressive technology, and look forward to establishing multiple partnerships across the globe.
If you would like to know more, please contact us on action@aagami.com